Navigation Links
Isis Reports Financial Results and Highlights for Second Quarter of 2008
Date:8/7/2008

h GlaxoSmithKline

-- Obtained exclusive rights from Stanford University to worldwide patent

applications covering methods and compositions for antagonizing

miR-181a

-- Selected as one of the FierceBiotech's 'Fierce 15' for 2008

Ibis Biosciences

-- Received an additional $20 million investment from Abbott for a total

of 18.6 percent equity in Ibis, retaining Abbott's exclusive option to

purchase remaining equity by June 30, 2009

-- Extended government contracts that add to Ibis' revenue and fund the

expansion of applications of the Ibis T5000 technology

Conference Call

At 8:30 a.m. Eastern Time today, August 7, Isis will conduct a live webcast conference call to discuss this earnings release and related activities. Interested parties may access the webcast at http://www.isispharm.com or listen to the call by dialing 877-627-6585. A webcast replay will be available for a limited time at the same address.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 18 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Ibis Biosciences, Inc., Isis' majority-owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. Isis is a joint owner of Regulus Therapeutics LLC, a joint venture focused on the discovery, development and commercialization of microRNA therapeutics. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 iss
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
2. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
3. Caliper Life Sciences Reports Second Quarter 2008 Results
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. EntreMed Reports Second Quarter 2008 Financial Results
6. Transgenomic Reports Second Quarter 2008 Results
7. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
8. Bionovo Reports Second Quarter 2008 Financial Results
9. AtriCure Reports Record Second Quarter 2008 Financial Results
10. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
11. eResearchTechnology Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 29, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: ... selected an optimized Erk inhibitor molecule for development, ... of a new class of potential cancer therapies. ... prime target for therapeutic intervention in cancer. Recently ... benefits for B-Raf and Mek inhibitors. Erk inhibitors ...
(Date:7/29/2015)... (PRWEB) , ... July 29, 2015 , ... Costello served ... levee system to protect the Orange County, Texas area from future storm surge ... design team in determining several potential levee alignment alternatives for providing protection, Costello also ...
(Date:7/28/2015)... , July 29, 2015 ... acquiring, rapidly developing and commercialising innovative ... health   Highly experienced management team; blue ...   Mereo BioPharma Group Ltd ("Mereo"), ... raised $119m ( c. £76.5m), gross, from blue chip ...
(Date:7/28/2015)... 28, 2015 People with a common form ... significant and sometimes profound improvements in their hearing and ... to a new multicenter study led by specialists at ... described online ahead of print in the journal The Laryngoscope ... clinics in the United States ...
Breaking Biology Technology:Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3Preventing Storm Surge Flooding in Houston 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 2Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 3Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 4Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 5Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 6Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 7Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 8Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 9Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 10Mereo BioPharma Announces Formal Launch of Company; Raises $119m (c.£76.5m) and Acquires Innovative Mid-Stage Clinical Product Portfolio From Leading Pharmaceutical Company 11Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 2Hybrid Cochlear Implants For Common Form Of Hearing Loss May Benefit Millions 3
... of smaller and faster, the next breakthroughs in the ... and data storage devices created out of novel materials ... techniques and new ways to position the molecules, NIST ... Physical Society how they have improved manipulation of so-called ...
... MONTVALE, N.J., March 12 Barr,Pharmaceuticals, Inc. (NYSE: ... - Lachema a.s., has received final approval from ... generic version of Bristol-Myers Squibb,Company,s Taxol(R) (paclitaxel) Injection ... Multiple-dose Vials. The Company plans to,launch its product ...
... Acquisition to Expand Company,s Market Position and Portfolio in Pain ... ... March 12 China Aoxing,Pharmaceutical Company, Inc. (OTC Bulletin Board: CAXG), ... medicines and pain medication in China, today announced that Hebei,Aoxing Pharmaceutical ...
Cached Biology Technology:Copolymers block out new approaches to microelectronics at NIST 2Barr Receives Approval for Generic Taxol(R) Injection USP, 6mg/mL 2Barr Receives Approval for Generic Taxol(R) Injection USP, 6mg/mL 3China Aoxing Pharmaceutical Company Signed Definitive Acquisition Agreement to Acquire Shijiazhuang Lerentang Pharmaceutical Company, Ltd. 2China Aoxing Pharmaceutical Company Signed Definitive Acquisition Agreement to Acquire Shijiazhuang Lerentang Pharmaceutical Company, Ltd. 3
(Date:7/2/2015)... , July 2, 2015 Fingerprint Cards ... FPC1035, FPC1145 and FPC1155 from the distributor World Peace Industrial ... FPC,s distributors in Asia . Deliveries are ... sensors will be used by smartphone manufacturers in ... included in the communicated revenue guidance of approximately 2,200 MSEK ...
(Date:6/26/2015)... , June 26, 2015 ATL Technology, LLC, ... devices with specialties in single use solutions, headquartered in ... MedConx, Inc. (a California corporation with ... San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing facility in ...
(Date:6/24/2015)... NEW YORK , June 24, 2015 ... favorable rate. The major drivers for the market include ... increasing number of new drug launches. Over the years, ... has increased. Between 2001 and 2010, the FDA approved ... addition, according to WIPO, Europe ...
Breaking Biology News(10 mins):FPC Receives Order for Touch Fingerprint Sensors of 268 MSEK 2ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4
... of aging in the nematode model organism C. elegans has provided ... whether genes involved in aging in the worm have a similar ... colleagues of McGill University (Canada) report that inactivation of the gene ... in increased cellular fitness and prolonged lifespan in mice. ...
... below your eyes. If you don't snooze, you lose a ... can't regenerate as quickly, the mind can't learn new words, ... gain things: a bad mood and increased risk for diabetes, ... sleep deprivation can be so serious that some sleep scientists ...
... offers additional insight into the evolutionary process by ... including New York University Biology Professor Richard Borowsky, ... that albinism in both populations was linked to ... common form of albinism in humans. They observed ...
Cached Biology News:Evolutionary conservation of a mechanism of longevity from worms to mammals 2Clocking in Pillow Time without the Pillow 2Clocking in Pillow Time without the Pillow 3Genetic analysis of cavefish reveals more about evolution 2
... fast and reliable automation for today's ... development laboratories. Staccato Mini-Workstations offer the ... basic liquid handling and material management ... either Caliper's time proven CLARA™ assay ...
Caliper offers a wide array of standard LabChip products designed to be used in combination with our AMS 90 and LabChip 3000 microfluidic platforms....
... to achieve high experimental throughput, minimum ... output 4 up to 16 ... requirements provides users with proven fermentation ... pastoris, yeast, fungi or any other ...
Experion HighSens chips are the microfluidic chips used to perform high-sensitivity RNA analysis (picogram levels) with the Experion automated electrophoresis system. Each chip has the capacity to ru...
Biology Products: